Recipient of federal assistance · DURHAM, NC

ELDEC PHARMACEUTICALS, INC.

ELDEC PHARMACEUTICALS, INC. received $903.2K in federal grants and other assistance in FY2026, on 7 actions, +222% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $5.8M. Its largest awarding agency was National Institutes of Health ($903.2K).

Assistance · FY2026
$903.2K
New awards
0
Actions
7
Since FY2021
$5.8M
UEI
LJBWLKDBEM17
Location
DURHAM, NC
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 999.8KFY2021
  2. 2.3MFY2022
  3. 1.3MFY2023
  4. 0FY2024
  5. 280.1KFY2025
  6. 903.2KFY2026

By type

  1. Grants$903.2K100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research$908K100%
  2. 93.855 · Allergy and Infectious Diseases Research-$4,8240.0%

Awarding agencies

  1. National Institutes of Health$903.2K100%
    Department of Health and Human Services

Largest awards

  1. ELD607 ORAI1 ANTAGONIST INCREASES BACTERIAL CLEARANCE FROM THE LUNG$2.3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Nov 2, 2020 – Dec 19, 2025· R42AI155107
  2. NOVEL PEPTIDE THERAPEUTICS TO TREAT CYSTIC FIBROSIS-RELATED DIABETES - CYSTIC FIBROSIS-RELATED DIABETES (CFRD) AFFECTS ~45% OF CF ADULTS…$1.2M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Sep 12, 2025 – Sep 16, 2026· R42DK145320
  3. NOVEL PEPTIDE FUSION INHIBITORS FOR THE TREATMENT OF COVID-19 - PROJECT SUMMARY COVID-19 IS CAUSED BY INHALATION OF THE LATEST CORONAVIRUS…$295.2K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 23, 2022 – Dec 16, 2025· R41AI162083
  4. NOVEL PEPTIDE IMMUNOMODULATORS FOR TREATING SEPSIS - NOVEL PEPTIDE IMMUNOMODULATORS FOR TREATING SEPSIS SEPSIS IS A LIFE-THREATENING…$259.1K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· May 3, 2023 – Jul 16, 2026· R43AI174395

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.